JP2021536237A5 - - Google Patents
Info
- Publication number
- JP2021536237A5 JP2021536237A5 JP2021510710A JP2021510710A JP2021536237A5 JP 2021536237 A5 JP2021536237 A5 JP 2021536237A5 JP 2021510710 A JP2021510710 A JP 2021510710A JP 2021510710 A JP2021510710 A JP 2021510710A JP 2021536237 A5 JP2021536237 A5 JP 2021536237A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- motif
- treg
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024111754A JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1814203.4 | 2018-08-31 | ||
| GBGB1814203.4A GB201814203D0 (en) | 2018-08-31 | 2018-08-31 | Engineered regulatory t cell |
| PCT/GB2019/052422 WO2020044055A1 (en) | 2018-08-31 | 2019-08-30 | Engineered regulatory t cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111754A Division JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021536237A JP2021536237A (ja) | 2021-12-27 |
| JP2021536237A5 true JP2021536237A5 (enExample) | 2022-09-05 |
Family
ID=63920789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510710A Pending JP2021536237A (ja) | 2018-08-31 | 2019-08-30 | 改変された制御性ｔ細胞 |
| JP2024111754A Pending JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111754A Pending JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210338726A1 (enExample) |
| EP (1) | EP3844264A1 (enExample) |
| JP (2) | JP2021536237A (enExample) |
| KR (1) | KR20210054543A (enExample) |
| CN (1) | CN112969784A (enExample) |
| AU (1) | AU2019333012A1 (enExample) |
| CA (1) | CA3110012A1 (enExample) |
| GB (2) | GB201814203D0 (enExample) |
| IL (1) | IL280942A (enExample) |
| SG (1) | SG11202101668TA (enExample) |
| WO (1) | WO2020044055A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3714944A1 (en) * | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| AU2019227979B2 (en) | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| US12227756B2 (en) | 2018-04-18 | 2025-02-18 | Ucl Business Ltd | Engineered regulatory T cell |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| IL285941B1 (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
| BR112022003553A2 (pt) | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| PE20221757A1 (es) | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| US20230138428A1 (en) * | 2020-02-25 | 2023-05-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| US20230149465A1 (en) * | 2020-04-06 | 2023-05-18 | Celledit Llc | Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling |
| CN111393533B (zh) * | 2020-04-16 | 2021-05-11 | 成都仕康美生物科技有限公司 | 靶向HLA-A的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途 |
| GB202007842D0 (en) | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| JP2023527459A (ja) * | 2020-06-01 | 2023-06-28 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | 誘導性制御性ｔ細胞、その生成方法及び使用 |
| WO2021250428A1 (en) | 2020-06-11 | 2021-12-16 | Quell Therapeutics Limited | Trem2 chimeric receptor |
| CN111849916B (zh) * | 2020-07-21 | 2021-08-27 | 广东先康达生物科技有限公司 | 一种免疫细胞及其制剂与应用 |
| GB202013477D0 (en) | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| GB202017678D0 (en) | 2020-11-09 | 2020-12-23 | Quell Therapeutics Ltd | Method for cryopreserving engineered tregs |
| IL302591A (en) | 2020-11-09 | 2023-07-01 | Quell Therapeutics Ltd | Method for cryopreservation of transgenic regulatory T cells |
| EP4267601A1 (en) | 2020-12-23 | 2023-11-01 | Quell Therapeutics Limited | Inducible signalling protein |
| EP4352209A4 (en) * | 2021-06-08 | 2025-07-16 | Methodist Hospital | METHODS FOR PRODUCING REGULATORY T CELL (TREG) POPULATIONS, TREG COMPOSITIONS, AND METHODS OF TREATMENT |
| GB202108364D0 (en) | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Chimeric receptor |
| GB202108366D0 (en) | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Multichain chimeric antigen receptor |
| WO2023047100A1 (en) | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-trem2 chimeric antigen receptor |
| TW202321286A (zh) | 2021-09-21 | 2023-06-01 | 英商圭爾醫療有限公司 | 抗p75ntr嵌合抗原受體 |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| WO2023102712A1 (zh) * | 2021-12-07 | 2023-06-15 | 深圳市先康达生命科学有限公司 | 一种基因生物制剂及其制备方法和应用 |
| US20250017967A1 (en) | 2021-12-17 | 2025-01-16 | Quell Therapeutics Limited | Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells |
| EP4453022A1 (en) | 2021-12-22 | 2024-10-30 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| WO2023156587A1 (en) * | 2022-02-18 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance |
| EP4496883A1 (en) | 2022-03-22 | 2025-01-29 | Quell Therapeutics Limited | Methods and products for culturing t cells and uses thereof |
| EP4577222A2 (en) * | 2022-08-26 | 2025-07-02 | Sonoma Biotherapeutics, Inc. | Tethered interleukin-2 recombinant receptors and methods of use |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| JP2026507781A (ja) | 2023-01-23 | 2026-03-06 | メディツィニシェ ホゥーシュル ハノーファー | キメラ抗原受容体 |
| CN120787258A (zh) | 2023-02-07 | 2025-10-14 | 圭尔医疗有限公司 | Treg细胞培养方法 |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194642A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t regulatory cell |
| WO2024254450A1 (en) * | 2023-06-07 | 2024-12-12 | Cellmidi Company Limited | Improved endodomains and immune cells comprising the same |
| CN121586727A (zh) | 2023-06-21 | 2026-02-27 | 圭尔医疗有限公司 | 组成型细胞因子受体 |
| CN117947070A (zh) * | 2024-02-01 | 2024-04-30 | 中山大学附属第三医院 | 一种嵌合抗原受体基因及其应用 |
| US20260176598A1 (en) | 2024-07-04 | 2026-06-25 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| US20160145348A1 (en) * | 2013-03-14 | 2016-05-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| CA2974998C (en) * | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| CA3004299A1 (en) * | 2015-11-05 | 2017-05-11 | City Of Hope | Methods for preparing cells for adoptive t cell therapy |
| CN109072194B (zh) * | 2015-12-09 | 2022-12-27 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物及其使用方法 |
| US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| MA45498A (fr) * | 2016-06-16 | 2019-04-24 | Memorial Sloan Kettering Cancer Center | Cellules treg génétiquement modifiées |
| CA3034691A1 (en) * | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| EP4119552A1 (en) * | 2017-02-08 | 2023-01-18 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| CN110678190A (zh) * | 2017-03-28 | 2020-01-10 | 宾夕法尼亚大学董事会 | 保护移植的组织免受排斥的方法 |
-
2018
- 2018-08-31 GB GBGB1814203.4A patent/GB201814203D0/en not_active Ceased
-
2019
- 2019-08-30 CA CA3110012A patent/CA3110012A1/en active Pending
- 2019-08-30 KR KR1020217009384A patent/KR20210054543A/ko active Pending
- 2019-08-30 CN CN201980067986.5A patent/CN112969784A/zh active Pending
- 2019-08-30 JP JP2021510710A patent/JP2021536237A/ja active Pending
- 2019-08-30 SG SG11202101668TA patent/SG11202101668TA/en unknown
- 2019-08-30 AU AU2019333012A patent/AU2019333012A1/en not_active Abandoned
- 2019-08-30 GB GB2104653.7A patent/GB2591929B/en active Active
- 2019-08-30 US US17/272,126 patent/US20210338726A1/en active Pending
- 2019-08-30 EP EP19763058.5A patent/EP3844264A1/en active Pending
- 2019-08-30 WO PCT/GB2019/052422 patent/WO2020044055A1/en not_active Ceased
-
2021
- 2021-02-17 IL IL280942A patent/IL280942A/en unknown
-
2024
- 2024-07-11 JP JP2024111754A patent/JP2024138456A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2591929A (en) | Engineered regulatory T Cell | |
| Leung | Use of NK cell activity in cure by transplant | |
| Castro-Manrreza et al. | Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications | |
| CN110506110B (zh) | 产生t细胞祖细胞的方法 | |
| JP5937003B2 (ja) | 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性ｔ細胞のエクスビボ増加方法 | |
| GB2609103A (en) | Chimeric receptors for use in engineered cells | |
| US20250283040A1 (en) | Methods to Expand a T Regulatory Cell Master Cell Bank | |
| EP4545639A2 (en) | Engineered gamma delta t-cells | |
| JP2008508885A5 (enExample) | ||
| JP2019536461A5 (enExample) | ||
| JP2020513844A5 (enExample) | ||
| JP2019050826A (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| JP2018533625A5 (enExample) | ||
| WO2017015490A1 (en) | T cells for expression of chimeric antigen receptors and other receptors | |
| WO2006050138A2 (en) | Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use | |
| US10758573B2 (en) | Compositions and methods for enrichment of cells | |
| EP3882337A1 (en) | Compositions and methods for diminishing an immune response | |
| CN102876630A (zh) | 一种高效分离和扩增人脐带血间充质干细胞的方法 | |
| JP2016539635A (ja) | 抗原特異的調節性ｔ細胞の誘導方法 | |
| JP2023138660A5 (enExample) | ||
| GB2614158A (en) | Nucleic acid constructs for expressing polypeptides in cells | |
| Moirangthem et al. | A DL-4-and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors | |
| US20170106021A1 (en) | Compositions enriched for hox11+ stem cells and methods of preparing the same | |
| JP2007521803A (ja) | レギュレーター／サプレッサーｔリンパ球の同定および調製のための方法、その組成物、並びにその使用 | |
| Marimuthu et al. | Elucidating the role of cell‐mediated inflammatory cytokines on allogeneic mouse‐derived nucleus pulposus mesenchymal stem cells |